Total Payments
$22,189
2019 Payments
$30.87
Companies
6
Transactions
15
Medicare Patients
105
Medicare Billing
$7,346
Payment Breakdown by Category
Research$22,051 (99.4%)
Food & Beverage$138.45 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22,051 | 8 | 99.4% |
| Food and Beverage | $138.45 | 7 | 0.6% |
Payments by Type
Research
$22,051
8 transactions
General
$138.45
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Circassia Pharmaceuticals Inc | $22,051 | 8 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $46.05 | 2 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $41.27 | 2 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $22.91 | 1 | $0 (2017) |
| AbbVie, Inc. | $14.43 | 1 | $0 (2017) |
| Amgen Inc. | $13.79 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $30.87 | 2 | Regeneron Healthcare Solutions, Inc. ($17.08) |
| 2018 | $70.24 | 3 | Novartis Pharmaceuticals Corporation ($46.05) |
| 2017 | $22,088 | 10 | Circassia Pharmaceuticals Inc ($22,051) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/13/2019 | Regeneron Healthcare Solutions, Inc. | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/11/2019 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: Inflammation | ||||||
| 08/28/2018 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: IMMUNOLOGY | ||||||
| 04/13/2018 | Regeneron Healthcare Solutions, Inc. | KEVZARA SARILUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/20/2018 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: IMMUNOLOGY | ||||||
| 06/07/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $503.00 | Research |
| Study: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | ||||||
| 06/06/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $15,070.80 | Research |
| Study: A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | ||||||
| 05/15/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $1,090.80 | Research |
| Study: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | ||||||
| 03/22/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $1,156.00 | Research |
| Study: A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | ||||||
| 02/10/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $421.20 | Research |
| Study: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | ||||||
| 02/03/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $2,973.60 | Research |
| Study: A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | ||||||
| 02/03/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $414.00 | Research |
| Study: A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | ||||||
| 02/03/2017 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $22.91 | General |
| Category: Immunology | ||||||
| 01/16/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $421.20 | Research |
| Study: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | ||||||
| 01/06/2017 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $19,614 | 4 |
| An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | Circassia Pharmaceuticals Inc | $2,436 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 27 | 41 | $16,795 | $1,751 |
| 2022 | 1 | 23 | 35 | $14,078 | $2,080 |
| 2021 | 1 | 20 | 33 | $13,200 | $1,669 |
| 2020 | 2 | 35 | 49 | $14,030 | $1,846 |
Total Patients
105
Total Services
158
Medicare Billing
$7,346
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 28 | $11,200 | $1,438 | 12.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 13 | $5,595 | $313.86 | 5.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 35 | $14,078 | $2,080 | 14.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 20 | 33 | $13,200 | $1,669 | 12.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 17 | 31 | $10,900 | $1,069 | 9.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 18 | 18 | $3,130 | $776.86 | 24.8% |
About Dr. Harold Keiser, MD
Dr. Harold Keiser, MD is a Rheumatology healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245320951.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harold Keiser, MD has received a total of $22,189 in payments from pharmaceutical and medical device companies, with $30.87 received in 2019. These payments were reported across 15 transactions from 6 companies. The most common payment nature is "" ($22,051).
As a Medicare-enrolled provider, Keiser has provided services to 105 Medicare beneficiaries, totaling 158 services with total Medicare billing of $7,346. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Bronx, NY
- Active Since 10/13/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1245320951
Products in Payments
- COSENTYX (Biological) $46.05
- KEVZARA SARILUMAB INJECTION (Biological) $24.19
- ORENCIA (Biological) $22.91
- KEVZARA (Biological) $17.08
- Humira (Biological) $14.43
- Enbrel (Biological) $13.79
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Bronx
Dr. Vinita Patel, D.o, D.O
Rheumatology — Payments: $133,682
Rheumatology $133,682
Arlene Tieng
Rheumatology — Payments: $83,727
Rheumatology $83,727
Dr. Sandeep Gupta, M.d, M.D
Rheumatology — Payments: $24,757
Rheumatology $24,757
Chaim Putterman, Md, MD
Rheumatology — Payments: $23,789
Rheumatology $23,789
David Engelbrecht, M.d, M.D
Rheumatology — Payments: $4,134
Rheumatology $4,134
Dr. Monalyn Zouzias, Md, MD
Rheumatology — Payments: $3,290
Rheumatology $3,290